 Two months after KalVista Pharmaceuticals Inc NASDAQ: KALV reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the effects of swelling attacks caused by the rare genetic disorder hereditary angioedema HAE, the FDA has issued a hold on their Phase 2 study of KVD824, an oral drug to prevent HAE. The FDA letter requests further information and analysis related to certain preclinical studies of KVD824 submitted to support the planned Phase 2 trial. 